Read this company snapshot
Daily valuation snapshot
Sinovac Biotech, Ltd: source evidence dated 2019-02-22.
- Daily close (USD)
- $6.47
- Market capitalization (USD)
- $370,613,640.67
- Price / earnings (TTM)
- 14.36
- Price / book
- 2.09
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research SVA in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research SVA in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2019-02-22. TTM means trailing twelve months. Use the market date when comparing SVA with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $6.47 |
| Market capitalization (USD) | $370,613,640.67 |
| Price / earnings (TTM) | 14.36 |
| Price / book | 2.09 |
No matching rows. Clear the filter to see all records.
Read SVA's valuation metrics
Company size
Sinovac Biotech, Ltd's recorded market capitalization is $370,613,640.67. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
SVA's recorded P/E is 14.36: about $14.36 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
SVA's recorded price-to-book ratio is 2.09. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Sinovac Biotech, Ltd with Aurora
Use the snapshot above to ask a specific question about SVA. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow SVA's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.